Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Arm Holdings plc (ARM) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade

Arm Holdings plcTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Arm Holdings plc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Arm Holdings plc trades at $313.01 (market cap $345.41B). The key difference: Arm Holdings plc is far larger — about 8.7× Alnylam Pharmaceuticals, Inc.'s market cap, and Arm Holdings plc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.

	ALNY	ARM
Market Cap	$39.89B	$345.41B
Sector	Health	Technology
52-Week High	$491.22	$439.46
52-Week Low	$278.09	$104.55
Enterprise Value	$38.15B	$342.26B

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.

Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.

Arm Holdings plc

ARM Holdings trades at $323.39, down 1.37% over 24 hours, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. The company reported robust revenue growth to $4.01B in 2025, with net income of $792M, though valuation ratios like P/E of 380.46 reflect premium pricing. Recent news highlights ARM's role in AI infrastructure and data center expansion, driving investor optimism.

Outlook remains positive with analyst consensus favoring buy ratings (74.07%) and a $321.65 price target, but risks include high valuation sensitivity and competitive pressures in the semiconductor space. Upside potential hinges on continued AI-driven demand and execution of growth initiatives like the AGI CPU launch.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ALNY

View details →

ARM

REX AI Equity Premium Income ETF shifts to weekly payouts, but income sustainability is uncertain.24/7 Wall Street · 15 hours agoNeutral Global Edge AI semiconductor market to reach $151.3B by 2035, driven by AI adoption in devices and industries.Sns Insider · 3 days agoBullish Micron boosts US semiconductor supply chain with $3B investment and $500M for wafer expansionCNBC · 4 days agoBullish View details →

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

About Arm Holdings plc

Arm Holdings designs the architecture for high-performance, energy-efficient processors used in nearly all smartphones and millions of other devices. Its intellectual property powers global computing from mobile to AI.